8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the CRD and CHE Technology Assessment Group, University of York:

  • Wade R, Duarte A et al. Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, April 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Sanofi

II. Professional/specialist and patient/carer groups:

  • Beating Bowel Cancer

  • Cancer Research UK

  • Royal College of Nursing

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Pfizer

  • Roche

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on aflibercept by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Richard Adams, Senior Lecturer and Consultant Oncologist, Velindre Cancer Centre and Cardiff University, nominated by Sanofi - clinical specialist

  • Jacqueline Fraser, nominated by Beating Bowel Cancer - patient expert

  • Helen Minnery, nominated by Beating Bowel Cancer - patient expert

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Sanofi

  • National Institute for Health and Care Excellence (NICE)